Volume 16, Issue 9, Pages 1123-1132 (September 2015) Effect of mammographic screening from age 40 years on breast cancer mortality in the UK Age trial at 17 years' follow-up: a randomised controlled trial Prof Sue M Moss, PhD, Christopher Wale, MSc, Robert Smith, PhD, Prof Andrew Evans, FRCR, Prof Howard Cuckle, DPhil, Prof Stephen W Duffy, MSc The Lancet Oncology Volume 16, Issue 9, Pages 1123-1132 (September 2015) DOI: 10.1016/S1470-2045(15)00128-X Copyright © 2015 Elsevier Ltd Terms and Conditions
Figure 1 Trial profile PNL=prior notification list. NHSBSP=National Health Service Breast Screening Programme. NHSCR=National Health Service Central Register. The Lancet Oncology 2015 16, 1123-1132DOI: (10.1016/S1470-2045(15)00128-X) Copyright © 2015 Elsevier Ltd Terms and Conditions
Figure 2 Nelson-Aalen estimate of cumulative breast cancer mortality (restricted to deaths from breast cancers diagnosed in the intervention phase) The Lancet Oncology 2015 16, 1123-1132DOI: (10.1016/S1470-2045(15)00128-X) Copyright © 2015 Elsevier Ltd Terms and Conditions
Figure 3 Nelson-Aalen estimate of cumulative breast cancer mortality (all dates of diagnosis) The Lancet Oncology 2015 16, 1123-1132DOI: (10.1016/S1470-2045(15)00128-X) Copyright © 2015 Elsevier Ltd Terms and Conditions
Figure 4 Rate ratio of breast cancer mortality in the intervention group, according to period of diagnosis of breast cancer The Lancet Oncology 2015 16, 1123-1132DOI: (10.1016/S1470-2045(15)00128-X) Copyright © 2015 Elsevier Ltd Terms and Conditions
Figure 5 Cumulative incidence of in-situ and invasive breast cancer (A), in-situ breast cancer alone (B), or invasive breast cancer alone (C) The Lancet Oncology 2015 16, 1123-1132DOI: (10.1016/S1470-2045(15)00128-X) Copyright © 2015 Elsevier Ltd Terms and Conditions